now occurring in the acute leukemias.\textsuperscript{4,9} In particular, clinical testing of BRAF inhibitors, alone or in combination with MEK inhibitors as in melanoma, as well as to cytokine-mediated pathways and immunologically selective targets, should be moved rapidly into clinical trials with the intention of improving both initial and prolonged responses.

In spite of the positive outcomes of the international LCH trials, a significant failure has been the lack of biological banking of tumor and germ line samples, which has been so effectively done for pediatric cancers through the cooperative groups. Future trials have an obligation to patients to assure that such banking is accomplished and samples made available to the international research community. In this era of genomics, a disease being “rare” is not an excuse for not ensuring detailed analysis of samples or not performing definitive clinical trials.

Two final points should be noted. First, it must be acknowledged that no international trial has been in effect since 2008, but LCH IV, just now moving forward, will attempt to address the issues of early mortality and further reduction in disease reactivation. Although sometimes either advisable and/or unavoidable, such gaps may miss important opportunities. Second, the immense progress made by the international trials has focused on children and not adults. Adults have become the true orphans of this orphan disease.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

REFERENCES

targeting of the GPIb-vWF interaction might be therapeutically beneficial in acute stroke. The current study by Momi et al1 demonstrates that ALX-0081, a divalent humanized nanobody directed against the GPIb-binding site on vWF (A1 domain), effectively dissolved newly formed intracranial thrombi leading to reperfusion and reduced infarct size in guinea pigs (see figure). ALX-0081 treatment was as effective as tPA in re-establishing cerebral blood flow when given at early but not late time points after vessel occlusion, indicating that it only exerts its thrombolytic activity before the thrombus is stabilized by fibrin formation and possibly other interactions that are not established at early phases. This is the first demonstration that a newly formed thrombus within the cerebral circulation can be dissolved by targeting platelet adhesion mechanisms, indicating that platelet-platelet interactions in such early thrombi are principally reversible and therefore “druggable.” Moreover, ALX-0081 reduced microvascular thrombus formation in the ischemic brain parenchyma at a stage when it was no longer effective as a thrombolytic agent at the site of the major stroke-inducing middle cerebral artery clot. In contrast, the GPIIIa inhibitor tirofiban obviously had no effect on microvascular patency, which is in agreement with previous observations in humans and mice where GPIIb/IIIa inhibition had no beneficial effect on infarct progression.5,6

How can the divergent effects between GPIIb/IIIa and GPIb-vWF–targeted treatment strategies be explained? Thrombus formation requires both platelet tethering via GPIb-vWF and platelet aggregation via GPIIb/IIIa. However, increasing experimental evidence suggests that ischemic brain infarction is not simply the consequence of thrombotic occlusion of intracerebral vessels, but that it also has an acute inflammatory component that links GPIb-vWF interactions to immune cell recruitment and breakdown of the blood brain barrier by unknown mechanisms.4 An involvement of GPIb-vWF interaction in immune cell recruitment and inflammation has also been demonstrated in other disease models such as experimental peritonitis.9 Thus, some of the effects seen with ALX-0081 nanobodies in the microvasculature in the study by Momi et al1 may be due to anti-inflammatory activity of the compound. Another remarkable result presented by Momi et al is the observation that ALX-0081 could be combined with low-dose tPA to improve thrombolytic activity without causing major intracranial hemorrhage. This confirms the previous notion that GPIb-vWF interactions are not required for maintaining vascular integrity in the ischemic brain, whereas GPIIb/IIIa appears to be absolutely critical.5,7

Given the multiple failures in improving acute stroke outcome by treatment with conventional platelet aggregation inhibitors such as acetylsalicylic acid10 and the GPIIb/IIIa inhibitors abciximab6 or tirofiban,7 the findings by Momi et al1 may pave the way for novel therapeutic options by targeting both primary thrombus formation and secondary thrombo-inflammatory processes during reperfusion of brain tissue.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

REFERENCES


(Dis)solving the stroke problem by vWF inhibition?

Bernhard Nieswandt and Guido Stoll